Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

D-Pharm Selects Tigermed for Trial of Stroke Drug

publication date: Nov 4, 2010
D-Pharm of Israel will entrust Hangzhou Tigermed Consulting Co. with a Phase III China clinical trial of its stroke treatment. Tigermed will also be in charge of China regulatory filings for DP-b99, a neuroprotective drug. Wanbang Biopharma, which will market the drug in China for D-Pharm, also signed the contract. More details....

Stock Symbol: (TASE: DPRM)

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020